989 related articles for article (PubMed ID: 29601269)
41. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
[TBL] [Abstract][Full Text] [Related]
42. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
43. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
[TBL] [Abstract][Full Text] [Related]
44. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.
Salipante SJ; Fromm JR; Shendure J; Wood BL; Wu D
Mod Pathol; 2014 Nov; 27(11):1438-46. PubMed ID: 24743218
[TBL] [Abstract][Full Text] [Related]
45. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
Dvorakova D; Racil Z; Jeziskova I; Palasek I; Protivankova M; Lengerova M; Razga F; Mayer J
Am J Hematol; 2010 Dec; 85(12):926-9. PubMed ID: 20981679
[TBL] [Abstract][Full Text] [Related]
46. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
[TBL] [Abstract][Full Text] [Related]
47. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
[TBL] [Abstract][Full Text] [Related]
48. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia.
Yu C; Kong QL; Zhang YX; Weng XQ; Wu J; Sheng Y; Jiang CL; Zhu YM; Cao Q; Xiong SM; Li JM; Xi XD; Chen SJ; Chen B
J Hematol Oncol; 2015 May; 8():48. PubMed ID: 25957890
[TBL] [Abstract][Full Text] [Related]
49. [Clinical and biological prognostic factors in relapsed acute myeloid leukemia patients].
Yébenes-Ramírez M; Serrano J; Martínez-Losada C; Sánchez-García J
Med Clin (Barc); 2016 Sep; 147(5):185-191. PubMed ID: 27374030
[TBL] [Abstract][Full Text] [Related]
50. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
[TBL] [Abstract][Full Text] [Related]
51. Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS.
Nakamura S; Yokoyama K; Shimizu E; Yusa N; Kondoh K; Ogawa M; Takei T; Kobayashi A; Ito M; Isobe M; Konuma T; Kato S; Kasajima R; Wada Y; Nagamura-Inoue T; Yamaguchi R; Takahashi S; Imoto S; Miyano S; Tojo A
Blood; 2019 Jun; 133(25):2682-2695. PubMed ID: 30936070
[TBL] [Abstract][Full Text] [Related]
52. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D
Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758
[TBL] [Abstract][Full Text] [Related]
53. Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing.
Slade MJ; Ghasemi R; O'Laughlin M; Burton T; Fulton RS; Abel HJ; Duncavage EJ; Ley TJ; Jacoby MA; Spencer DH
JCO Precis Oncol; 2023 Apr; 7():e2200559. PubMed ID: 37079859
[TBL] [Abstract][Full Text] [Related]
54. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.
Buckley SA; Wood BL; Othus M; Hourigan CS; Ustun C; Linden MA; DeFor TE; Malagola M; Anthias C; Valkova V; Kanakry CG; Gruhn B; Buccisano F; Devine B; Walter RB
Haematologica; 2017 May; 102(5):865-873. PubMed ID: 28126965
[TBL] [Abstract][Full Text] [Related]
55. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
56. CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission.
Ikegawa S; Doki N; Kurosawa S; Yamaguchi T; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Hattori K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Haraguchi K; Okuyama Y; Ohashi K
Leuk Lymphoma; 2016; 57(6):1375-81. PubMed ID: 26422713
[TBL] [Abstract][Full Text] [Related]
57. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
Kern W; Voskova D; Schoch C; Hiddemann W; Schnittger S; Haferlach T
Blood; 2004 Nov; 104(10):3078-85. PubMed ID: 15284114
[TBL] [Abstract][Full Text] [Related]
58. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
[TBL] [Abstract][Full Text] [Related]
59. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
60. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
Au CH; Wa A; Ho DN; Chan TL; Ma ES
Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]